GATA3 and cancer: The absence of false positive findings in these samples may be attributed to the stringent criteria for (a) BrAD-CTC enrichment, which is based on a hallmark characteristic of cancer, as well as for (b) BrAD-CTC detection, which is based on the positive expression of GATA3 and GCDFP15 in addition to EpCAM and PanCK.